48,453
edits
Difference between revisions of "Squamous cell carcinoma"
Jump to navigation
Jump to search
Squamous cell carcinoma (view source)
Revision as of 18:21, 21 September 2020
, 18:21, 21 September 2020→See also
| (3 intermediate revisions by the same user not shown) | |||
| Line 228: | Line 228: | ||
*[[p63]] +ve. | *[[p63]] +ve. | ||
*K903 +ve. | *K903 +ve. | ||
*p16 +ve/-ve -- dependent on site, +ve favours non-lung SCC.<ref name=pmid20823766/> | *[[p16]] +ve/-ve -- dependent on site, +ve favours non-lung SCC.<ref name=pmid20823766/> | ||
*[[p40]] +ve. | |||
Note: | |||
*Immunostains not particularly helpful for establishing primary site of squamous cell carcinoma. p16 may be helpful but is not definitive for non-lung SCC.<ref name=pmid20823766/> | |||
=See also= | =See also= | ||
*[[Adenocarcinoma]]. | *[[Adenocarcinoma]]. | ||
*[[Pseudoepitheliomatous hyperplasia]] - can mimic squamous cell carcinoma. | |||
*[[Basics]]. | *[[Basics]]. | ||